CNOT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4699731	1.00	2/20
SCHEMBL16111548	1.00	2/20
SCHEMBL29358745	1.00	2/20
SCHEMBL29380618	1.00	2/20
SCHEMBL29931136	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL24532075	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL23092285	0.86	2/20
SCHEMBL24532059	0.86	2/20
SCHEMBL29688472	0.86	2/20
SCHEMBL22024695	0.86	2/20
SCHEMBL16136600	0.84	2/20
SCHEMBL24532058	0.83	2/20
SCHEMBL4699947	0.83	2/20
SCHEMBL22025026	0.82	2/20
SCHEMBL22119546	0.82	2/20
SCHEMBL24532062	0.82	2/20
SCHEMBL18804561	0.81	2/20
SCHEMBL22024561	0.81	2/20

Clinical trials — most relevant to CNOT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men	PHASE3	ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma	PHASE1/PHASE2	RECRUITING
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia	PHASE1	COMPLETED
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma	PHASE1	COMPLETED
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN
The Genetics of Chiari Type I Malformation	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Genetic Studies Spermatogenic Failure	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy	nan	RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）	nan	RECRUITING
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Diagnosis of Inflammatory Bowel Disease	nan	NOT_YET_RECRUITING
Diagnosis of Primary Ciliary Dyskinesia	nan	COMPLETED
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy	nan	COMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections	nan	COMPLETED
Identification of Genetic Mutations Involved in Chiari Type I Malformations	nan	COMPLETED
Chromosome 5Q Gene Variants and Asthma-Related Traits	nan	COMPLETED
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CNOT1 binder may also engage these)

Protein	Name	Similarity
Q6ZQ08	—	1.000	Q6ZQ08 →
A0JP85	—	1.000	A0JP85 →
A1A5H6	—	1.000	A1A5H6 →
Q5F3M0	—	0.993	Q5F3M0 →
O94915	—	0.992	O94915 →
Q80YV3	—	0.992	Q80YV3 →
Q5RCU2	—	0.992	Q5RCU2 →
MED12	Mediator of RNA polymerase II transcription subunit 12	0.992	landscape →
A5GFY4	—	0.991	A5GFY4 →
Q24134	—	0.991	Q24134 →
B1AY13	—	0.990	B1AY13 →
Q99K74	—	0.990	Q99K74 →
USP24	Ubiquitin carboxyl-terminal hydrolase 24	0.990	landscape →
Q2PW47	—	0.990	Q2PW47 →
Q922L6	—	0.989	Q922L6 →
Q9Y3R5	—	0.989	Q9Y3R5 →
Q9VS24	—	0.988	Q9VS24 →
Q5TBA9	—	0.988	Q5TBA9 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.988	landscape →
Q80TJ1	—	0.988	Q80TJ1 →
Q8TC92	—	0.988	Q8TC92 →
Q8R1A4	—	0.988	Q8R1A4 →
A2AGH6	—	0.988	A2AGH6 →
E9Q8I9	—	0.988	E9Q8I9 →
A1CXW3	—	0.988	A1CXW3 →
Q9VW47	—	0.987	Q9VW47 →
A5D794	—	0.987	A5D794 →
Q6P4S8	—	0.987	Q6P4S8 →
Q4V8B3	—	0.987	Q4V8B3 →
Q9P2D8	—	0.987	Q9P2D8 →